INTRODUCTION
============

In the United States, gastric cancer is a devastating disease, with a 5-year overall survival of only 30.6% \[[@B1]\]. Surgical resection with adequate oncologic margins and removal of regional lymph nodes (LNs) offers the best hope for long-term survival. LN status is an important prognostic indicator in gastric cancer, with positive LNs suggesting a poor prognosis \[[@B2][@B3]\]. However, patients with node-negative disease still have a 17% chance of disease recurrence, and a 5-year overall survival of only 53% \[[@B4]\].

Extent of lymphadenectomy remains a controversial topic in surgical management of gastric cancer. In Japan, extended lymphadenectomy, referring to a D2 LN dissection, is standard of care \[[@B5]\]. However, initial data from randomized controlled trials in British and Dutch populations failed to find a significant survival benefit for D2 dissections over D1 dissections \[[@B6][@B7]\]. Long-term follow-up in the Dutch study found improved disease specific survival with D2 dissections \[[@B8]\]. In the United States, the National Comprehensive Cancer Network (NCCN) guidelines currently recommend gastrectomy with D1 or modified D2 LN dissection, with preservation of the distal pancreas and spleen; the surgeon should examine at least LNs \[[@B9]\]. Recent evidence from Asian populations demonstrates a survival benefit to increasing the number of examined lymph nodes (eLNs), even in node-negative disease \[[@B10][@B11][@B12][@B13]\]. However, this has not been explored in African, European, or North and South American populations. Given differences in gastric cancer between Asian and other populations, the results of these studies are not necessarily applicable to African, European, or North and South American populations. This study sought to determine whether number of eLN, a proxy for lymphadenectomy, effects survival in US patients with node-negative gastric cancer.

MATERIALS AND METHODS
=====================

Data
----

This was a retrospective cohort study using data from the National Cancer Data Base (NCDB). This clinical oncology database, jointly sponsored by the American College of Surgeons and the American Cancer Society, is sourced from hospital registry data collected from over 1,500 Commission on Cancer (CoC) accredited facilities. The NCDB captures over 70% of newly diagnosed cancer cases in the United States. The NCDB contains readily available de-identified data, and therefore this study was not subject to institutional review board approval or oversight.

Patient selection
-----------------

The NCDB (2003--2011) was reviewed for patients diagnosed with clinical stages I--III gastric cancer, who underwent surgical resection, with or without systemic therapy. Patients with clinical stage IV disease or unknown stage were excluded. Clinical stage is coded in the NCDB according to standard practice at each individual institution. Patients who did not undergo surgical resection were excluded. Patients were categorized by receipt of neoadjuvant therapy (NAT) vs. initial resection, and further stratified by number of eLN: ≤10, 11--15, 16--20, 21--30, and \>30.

Outcomes and covariates
-----------------------

The primary variable assessed was overall survival. Analyses controlled for patient and disease characteristics including age, sex, race, insurance type (private, Medicare, Medicaid and other government programs, unknown, and not insured), and the Charlson/Deyo comorbidity index (CCI), an index of 15 comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, diabetes, diabetes with chronic complications, hemiplegia or paraplegia, renal disease, moderate or severe liver disease, and acquired immunodeficiency syndrome) \[[@B14][@B15]\]. Median income of the patient\'s zip code was used as a proxy for socioeconomic status. Treatment facilities were characterized by type (community, comprehensive community, academic or research institution, other) and US geographic region (northeast, south, mid-west, west). Disease was characterized by the American Joint Committee on Cancer (AJCC) clinical stage, surgery type (proximal gastrectomy, total gastrectomy, distal gastrectomy, and surgery not otherwise specified), number of regional LNs removed, number of positive regional LNs, surgical margins (no residual tumor, residual tumor not otherwise specified, microscopic residual tumor, macroscopic residual tumor, and indeterminate and unknown margins), pathologic stage, and adjuvant therapy. The main covariate of interest was eLN, which was subdivided into 5 groups: ≤10, 11--15, 16--20, 21--30, and \>30 LNs.

Statistical analysis
--------------------

Statistical analyses were performed with Stata software (version 12.1; StataCorp., College Station, TX, USA). Patient, disease, and facility characteristics were compared within each cohort with analysis of variance for continuous variables and χ^2^ tests for categorical variables. Kaplan-Meier analyses were performed for each clinical stage and treatment, and stratified by eLN. The proportional hazards assumption was violated, and thus multivariable survival analyses were performed for each initial treatment using a Weibull model, controlling for covariates described above.

RESULTS
=======

From 2003 to 2011, the median number of eLN in node negative resected gastric cancer has steadily risen from 8 to 14 ([Fig. 1](#F1){ref-type="fig"}).

![Trends in median number of LN examined from 2003 to 2011.\
LN = lymph node; eLN = examined lymph node.](jgc-17-306-g001){#F1}

Patient characteristics of NAT cohort
-------------------------------------

Of the 1,036 (27%) who received NAT, 40.5% (n=420) had ≤10, 21.8% (n=226) had 11--15, 16.8% (n=174) had 16--20, 13.4% (n=139) had 21--30, and 7.4% (n=77) had \>30 eLN ([Fig. 2](#F2){ref-type="fig"}). Of those who received NAT, 58.0% underwent a suboptimal lymphadenectomy as defined according to NCCN guidelines (\<15 eLN).

![Distribution of eLNs in NAT cohort.\
eLN = examined lymph node; NAT = neoadjuvant therapy.](jgc-17-306-g002){#F2}

Patient, disease, and treatment characteristics of patients who received NAT, stratified by eLN, are presented in [Table 1](#T1){ref-type="table"}. Patients who received a suboptimal lymphadenectomy (eLN ≤10) tended to be male (P\<0.001), were more likely to be treated at a comprehensive community center (P\<0.001), and were more likely to undergo a proximal gastrectomy (P\<0.001). Age (P=0.915), race (P=0.395), comorbidities (P=0.785), surgical margins (P=0.225), and clinical and pathological stages (P=0.901 and P=0.124, respectively) did not significantly differ among eLN groups.

###### Patient, disease, and treatment characteristics of NAT cohort

![](jgc-17-306-i001)

  Variable                        ≤10 (n=420, %)                11--15 (n=226, %)   16--20 (n=174, %)   21--30 (n=139, %)   \>30 (n=77, %)   P-value
  ------------------------------- ----------------------------- ------------------- ------------------- ------------------- ---------------- ---------
  Age                             61.5                          61.4                60.9                62.0                61.0             0.915
                                  18--59                        41.2                39.4                38.5                38.8             45.5
                                  60--69                        35.7                39.4                42.5                34.5             27.3
                                  70--79                        20.7                19.5                18.4                23.7             24.7
                                  80--90                        2.4                 1.8                 0.6                 2.9              2.6
  Sex                                                                                                                                        \<0.001
                                  Male                          82.1                85.8                83.3                68.3             68.8
                                  Female                        17.9                14.2                16.7                31.7             31.2
  Race                                                                                                                                       0.395
                                  White (non-Hispanic)          84.8                86.7                85.6                81.3             75.3
                                  Black (non-Hispanic)          4.0                 3.5                 2.9                 7.9              6.5
                                  Other (non-Hispanic)          2.1                 2.2                 1.1                 2.9              3.9
                                  Hispanic                      9.0                 7.5                 10.3                7.9              14.3
  Insurance                                                                                                                                  0.260
                                  Private                       52.6                52.7                58.0                54.0             50.6
                                  Medicare                      38.3                38.9                33.9                38.1             35.1
                                  Medicaid & other government   6.9                 4.9                 6.3                 5.0              9.1
                                  Unknown                       0.5                 1.8                 1.7                 2.2              0.0
                                  Not insured                   1.7                 1.8                 0.0                 0.7              5.2
  Median income                                                                                                                              0.561
                                  \<58,000                      12.1                8.8                 12.1                11.5             15.6
                                  58,000--74,000                21.4                25.7                27.6                20.9             19.5
                                  74,000--93,000                26.7                28.8                27.0                29.5             19.5
                                  \>93,000                      36.7                34.5                31.0                34.5             42.9
  Comorbidities                                                                                                                              0.785
                                  CCI score 0                   73.3                75.7                76.4                75.5             79.2
                                  CCI score 1                   22.1                20.4                21.8                20.9             19.5
                                  CCI score 2                   4.5                 4.0                 1.7                 3.6              1.3
  Facility type                                                                                                                              \<0.001
                                  Community                     3.1                 5.8                 3.4                 2.9              1.3
                                  Comprehensive community       42.4                32.3                26.4                22.3             31.2
                                  Academic/research             54.0                61.9                70.1                74.8             67.5
                                  Other                         0.5                 0.0                 0.0                 0.0              0.0
  Facility location                                                                                                                          0.033
                                  Northeast                     18.8                22.1                25.9                30.2             29.9
                                  South                         36.9                35.4                32.2                27.3             33.8
                                  Midwest                       33.1                28.3                27.0                30.2             16.9
                                  West                          11.2                14.2                14.9                12.2             19.5
  Clinical stage                                                                                                                             0.901
                                  Stage II                      51.4                52.2                52.9                55.4             57.1
                                  Stage III                     48.3                47.8                46.6                44.6             42.9
  Surgery type                                                                                                                               \<0.001
                                  Proximal gastrectomy          74.0                69.9                67.8                54.7             50.6
                                  Total gastrectomy             19.0                23.0                24.7                40.3             40.3
                                  Distal gastrectomy            6.9                 7.1                 7.5                 5.0              9.1
  Regional lymph nodes examined   6.2                           13.0                17.7                24.5                39.0             \<0.001
  Surgical margins                                                                                                                           0.225
                                  No residual tumor             96.0                95.6                94.3                95.0             96.1
                                  Residual tumor, NOS           1.2                 1.3                 1.1                 2.9              0.0
                                  Microscopic residual tumor    2.1                 2.2                 2.3                 1.4              1.3
                                  Macroscopic residual tumor    0.0                 0.0                 0.0                 0.0              1.3
                                  Indeterminate or unknown      0.7                 0.9                 2.3                 0.7              1.3
  Pathological stage                                                                                                                         0.124
                                  Stage 0                       3.3                 3.5                 7.5                 2.9              2.6
                                  Stage 1                       29.0                32.7                24.7                31.7             41.6
                                  Stage 2                       36.9                36.7                37.4                34.5             32.5
                                  Stage 3                       3.1                 1.3                 4.0                 2.9              2.6
                                  Stage 4                       0.5                 0.4                 0.0                 0.0              2.6
                                  Unknown                       23.6                23.9                22.4                23.7             13.0

NAT = neoadjuvant therapy; CCI = Charlson/Deyo comorbidity index; NOS = not otherwise specified.

Survival of NAT Cohort
----------------------

Kaplan-Meier analyses of patients who received NAT are stratified by eLN and presented in [Fig. 3](#F3){ref-type="fig"}. Inadequate lymphadenectomy (eLN ≤10) was associated with worse survival in clinical stage II and III disease; however, this association was only significant in stage III disease (P=0.020).

![Survival by eLNs in NAT cohort.\
eLN = examined lymph node; NAT = neoadjuvant therapy.](jgc-17-306-g003){#F3}

Results of a Weibull survival model of patients who received NAT are presented in [Table 2](#T2){ref-type="table"}. A greater number of eLN was associated with improved hazards of mortality (eLN 16--20: HR, 0.71; P=0.039, eLN 21--30: HR, 0.55; P=0.001). Treatment at an academic center was also associated with a reduction in mortality (HR, 0.52, P=0.005). Greater age (80--90: HR, 3.52; P\<0.001) and coverage by Medicaid (HR, 1.59, P=0.019) were associated with increased hazards of mortality.

###### Factors impacting survival in NAT cohort

![](jgc-17-306-i002)

  Variable                      HR                            95% CI      P-value          
  ----------------------------- ----------------------------- ----------- --------- ------ ---------
  No. of lymph nodes examined                                                              
                                ≤10                           Reference                    
                                11--15                        0.86        0.66      1.11   0.246
                                16--20                        0.71        0.52      0.98   0.039
                                21--30                        0.55        0.38      0.79   0.001
                                \>30                          0.75        0.48      1.17   0.203
  Age                                                                                      
                                18--59                        Reference                    
                                60--69                        1.08        0.83      1.41   0.561
                                70--79                        1.54        1.09      2.17   0.014
                                80--90                        3.52        1.87      6.64   \<0.001
  Sex                                                                                      
                                Male                          Reference                    
                                Female                        0.96        0.74      1.25   0.757
  Race                                                                                     
                                White (non-Hispanic)          Reference                    
                                Black (non-Hispanic)          0.71        0.41      1.24   0.227
                                Other (non-Hispanic)          0.67        0.29      1.54   0.348
                                Hispanic                      1.05        0.75      1.48   0.777
  Insurance                                                                                
                                Private                       Reference                    
                                Medicare                      1.02        0.77      1.35   0.911
                                Medicaid & other government   1.59        1.08      2.35   0.019
                                Unknown                       0.82        0.26      2.61   0.738
                                Not insured                   1.67        0.77      3.65   0.195
  Median income                                                                            
                                \<58,000                      Reference                    
                                58,000--74,000                1.40        1.00      1.96   0.053
                                74,000--93,000                1.07        0.77      1.50   0.685
                                \>93,000                      0.92        0.66      1.29   0.645
  Comorbidities                                                                            
                                CCI score 0                   Reference                    
                                CCI score 1                   1.22        0.96      1.55   0.100
                                CCI score 2                   1.28        0.72      2.27   0.397
  Facility type                                                                            
                                Community                     Reference                    
                                Comprehensive community       0.52        0.32      0.83   0.007
                                Academic/research             0.52        0.33      0.82   0.005
                                Other                         1.05        0.14      8.14   0.961
  Facility location                                                                        
                                Northeast                     Reference                    
                                South                         1.18        0.89      1.56   0.249
                                Midwest                       0.99        0.74      1.33   0.963
                                West                          0.80        0.55      1.15   0.230
  Surgery type                                                                             
                                Proximal gastrectomy          Reference                    
                                Total gastrectomy             0.86        0.67      1.11   0.242
                                Distal gastrectomy            0.80        0.53      1.19   0.271
  Surgical margins                                                                         
                                No residual tumor             Reference                    
                                Residual tumor, NOS           2.05        1.05      4.01   0.035
                                Microscopic residual tumor    1.81        1.03      3.20   0.040
                                Macroscopic residual tumor    0.00        0.00      0.00   0.999
                                Indeterminate or unknown      1.09        0.39      2.99   0.874
  Pathological stage                                                                       
                                Stage 0                       Reference                    
                                Stage 1                       0.66        0.43      1.03   0.068
                                Stage 2                       0.99        0.65      1.52   0.970
                                Stage 3                       0.85        0.42      1.69   0.638
                                Stage 4                       2.04        0.71      5.90   0.188
                                Unknown                       0.62        0.39      0.98   0.041

NAT = neoadjuvant therapy; HR = hazard ratio; CI = confidence interval; CCI = Charlson/Deyo comorbidity index; NOS = not otherwise specified.

Patient characteristics of initial surgery cohort
-------------------------------------------------

Of the 2,795 patients who underwent initial surgery, 42.5% (n=1,187) had ≤10, 19.8% (n=553) had 11--15, 14.5% (n=404) had 16--20, 15.5% (n=432) had 21--30, and 7.8% (n=219) had \>30 eLN ([Fig. 4](#F4){ref-type="fig"}). Of those who underwent initial surgery, 58.6% underwent a suboptimal lymphadenectomy (\<15 eLN).

![Distribution of eLNs in initial surgery cohort.\
eLN = examined lymph node.](jgc-17-306-g004){#F4}

Patient, disease, and treatment characteristics of patients who underwent initial surgery are stratified by eLN and presented in [Table 3](#T3){ref-type="table"}. Patients who received a suboptimal lymphadenectomy (eLN ≤10) tended to be older (P\<0.001), white (P\<0.001), and treated at a comprehensive community center (P\<0.001). They tended to undergo a proximal gastrectomy (P\<0.001), and have a more advanced pathological stage (P=0.024). Clinical stage (P=0.192), surgical margins (P=0.161), and adjuvant therapy (P=0.061) did not significantly differ among eLN groups.

###### Patient, disease, and treatment characteristics of initial surgery cohort

![](jgc-17-306-i003)

  Variable                        ≤10 (n=1,187, %)              11--15 (n=553, %)   16--20 (n=404, %)   21--30 (n=432, %)   \>30 (n=219, %)   P-value
  ------------------------------- ----------------------------- ------------------- ------------------- ------------------- ----------------- ---------
  Age                             67.8                          66.8                66.3                64.9                65.1              \<0.001
                                  18--59                        23.8                25.5                28.2                32.2              26.5
                                  60--69                        27.0                32.0                28.7                28.2              35.2
                                  70--79                        32.4                28.8                30.0                27.5              29.7
                                  80--90                        16.8                13.7                13.1                12.0              8.7
  Sex                                                                                                                                         0.075
                                  Male                          68.0                72.7                68.6                67.4              62.6
                                  Female                        32.0                27.3                31.4                32.6              37.4
  Race                                                                                                                                        \<0.001
                                  White (non-Hispanic)          73.3                68.4                70.3                68.3              59.4
                                  Black (non-Hispanic)          9.0                 9.2                 6.7                 6.9               7.8
                                  Other (non-Hispanic)          5.1                 7.8                 7.2                 10.6              12.3
                                  Hispanic                      12.6                14.6                15.8                14.1              20.5
  Insurance                                                                                                                                   0.396
                                  Private                       33.6                35.4                39.6                39.8              39.3
                                  Medicare                      58.0                54.4                52.2                50.5              48.9
                                  Medicaid & other government   5.4                 6.1                 5.7                 5.8               8.2
                                  Unknown                       1.0                 1.1                 0.7                 1.4               1.4
                                  Not insured                   2.0                 2.9                 1.7                 2.5               2.3
  Median income                                                                                                                               0.202
                                  \<58,000                      15.5                15.9                14.1                13.7              13.7
                                  58,000--74,000                25.3                21.9                20.0                20.6              21.0
                                  74,000--93,000                23.5                26.0                26.2                29.2              25.1
                                  \>93,000                      32.8                33.3                38.4                35.0              38.8
  Comorbidities                                                                                                                               0.076
                                  CCI score 0                   62.0                65.1                65.8                69.2              70.8
                                  CCI score 1                   28.1                25.9                25.5                24.8              23.3
                                  CCI score 2                   9.9                 9.0                 8.7                 6.0               5.9
  Facility type                                                                                                                               \<0.001
                                  Community                     6.6                 5.2                 7.2                 4.2               4.6
                                  Comprehensive community       48.8                38.3                35.4                31.5              25.1
                                  Academic/research             44.4                56.2                56.9                64.4              70.3
                                  Other                         0.3                 0.2                 0.5                 0.0               0.0
  Facility location                                                                                                                           \<0.001
                                  Northeast                     20.8                23.5                27.5                29.9              37.4
                                  South                         39.9                33.3                30.2                23.4              22.4
                                  Midwest                       23.0                25.5                27.0                27.5              19.2
                                  West                          16.3                17.7                15.3                19.2              21.0
  Clinical stage                                                                                                                              0.192
                                  Stage I                       71.7                74.1                70.3                71.1              73.5
                                  Stage II                      15.2                13.7                19.8                16.9              17.4
                                  Stage III                     6.4                 6.7                 5.7                 8.6               5.5
  Surgery type                                                                                                                                \<0.001
                                  Proximal gastrectomy          63.4                57.1                54.2                51.4              41.1
                                  Total gastrectomy             26.9                32.9                36.1                40.7              50.7
                                  Distal gastrectomy            9.8                 9.9                 9.7                 7.9               8.2
  Regional lymph nodes examined   5.6                           12.9                17.9                24.7                38.7              \<0.001
  Surgical margins                                                                                                                            0.161
                                  No residual tumor             93.7                95.8                96.0                96.5              96.3
                                  Residual tumor, NOS           1.1                 1.1                 0.7                 0.9               0.5
                                  Microscopic residual tumor    4.2                 2.2                 1.5                 1.6               2.3
                                  Macroscopic residual tumor    0.3                 0.0                 0.7                 0.2               0.0
                                  Indeterminate or unknown      0.8                 0.9                 1.0                 0.7               0.9
  Pathological stage                                                                                                                          0.024
                                  Stage 0                       4.5                 3.3                 2.5                 2.5               2.3
                                  Stage 1                       68.4                70.7                71.0                71.1              73.5
                                  Stage 2                       14.9                14.6                19.1                16.7              16.9
                                  Stage 3                       4.4                 3.3                 2.2                 1.6               1.8
                                  Stage 4                       1.4                 0.7                 0.7                 0.5               0.9
                                  Unknown                       5.0                 6.1                 4.0                 6.7               4.1
  Adjuvant therapy                                                                                                                            0.061
                                  None                          86.7                90.1                85.1                88.4              83.6
                                  Adjuvant therapy              13.3                9.9                 14.9                11.6              16.4

CCI = Charlson/Deyo comorbidity index; NOS = not otherwise specified.

Survival of initial surgery cohort
----------------------------------

Kaplan-Meier analyses of patients who underwent initial surgery are stratified by eLN and presented in [Fig. 5](#F5){ref-type="fig"}. Inadequate lymphadenectomy with eLN ≤10 was associated with worse survival in clinical stage I--III diseases; however, this association was only significant in stages I and II (P\<0.001 and P=0.002, respectively).

![Survival by eLNs in initial surgery cohort.\
eLN = examined lymph node.](jgc-17-306-g005){#F5}

Results of a Weibull survival model of patients who underwent initial surgery are presented in [Table 4](#T4){ref-type="table"}. A greater number of eLN was associated with improved hazards of mortality (eLN 11--15: HR, 0.81; P=0.021, eLN 16--20: HR, 0.73; P=0.004, eLN 21--30: HR, 0.62; P\<0.001, and eLN \>30: HR, 0.58; P=0.001). Female sex, Hispanic or other race, greater median income, treatment at an academic or research center, and receipt of adjuvant therapy were also associated with a reduction in mortality. Greater age, coverage by Medicaid or Medicare, receipt of total gastrectomy, positive surgical margins, and advanced pathological stage were associated with increased hazards of mortality.

###### Factors impacting survival in initial surgery cohort
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  Variable                      HR                            95% CI      P-value           
  ----------------------------- ----------------------------- ----------- --------- ------- ---------
  No. of lymph nodes examined                                                               
                                ≤10                           Reference                     
                                11--15                        0.81        0.68      0.97    0.021
                                16--20                        0.73        0.59      0.91    0.004
                                21--30                        0.62        0.50      0.78    \<0.001
                                \>30                          0.58        0.43      0.80    0.001
  Age                                                                                       
                                18--59                        Reference                     
                                60--69                        1.25        1.00      1.57    0.054
                                70--79                        1.74        1.37      2.21    \<0.001
                                80--90                        2.86        2.21      3.69    \<0.001
  Sex                                                                                       
                                Male                          Reference                     
                                Female                        0.83        0.72      0.97    0.015
  Race                                                                                      
                                White (non-Hispanic)          Reference                     
                                Black (non-Hispanic)          0.88        0.68      1.14    0.347
                                Other (non-Hispanic)          0.54        0.38      0.75    \<0.001
                                Hispanic                      0.78        0.63      0.95    0.015
  Insurance                                                                                 
                                Private                       Reference                     
                                Medicare                      1.28        1.06      1.54    0.011
                                Medicaid & other government   1.38        1.01      1.90    0.046
                                Unknown                       2.62        1.49      4.62    0.001
                                Not insured                   1.06        0.58      1.92    0.851
  Median income                                                                             
                                \<58,000                      Reference                     
                                58,000--74,000                0.96        0.78      1.17    0.656
                                74,000--93,000                0.77        0.62      0.94    0.012
                                \>93,000                      0.76        0.62      0.93    0.008
  Comorbidities                                                                             
                                CCI score 0                   Reference                     
                                CCI score 1                   1.16        1.00      1.35    0.054
                                CCI score 2                   1.59        1.30      1.96    \<0.001
  Facility type                                                                             
                                Community                     Reference                     
                                Comprehensive community       0.81        0.62      1.05    0.117
                                Academic/research             0.72        0.56      0.94    0.016
                                Other                         0.71        0.17      2.92    0.632
  Facility location                                                                         
                                Northeast                     Reference                     
                                South                         1.08        0.90      1.30    0.396
                                Midwest                       0.93        0.77      1.14    0.495
                                West                          0.88        0.71      1.10    0.276
  Surgery type                                                                              
                                Proximal gastrectomy          Reference                     
                                Total gastrectomy             1.31        1.13      1.51    \<0.001
                                Distal gastrectomy            1.15        0.91      1.46    0.241
  Surgical margins                                                                          
                                No residual tumor             Reference                     
                                Residual tumor, NOS           2.14        1.29      3.55    0.003
                                Microscopic residual tumor    2.09        1.53      2.84    \<0.001
                                Macroscopic residual tumor    2.98        1.21      7.34    0.017
                                Indeterminate or unknown      1.31        0.64      2.65    0.457
  Pathological stage                                                                        
                                Stage 0                       Reference                     
                                Stage 1                       1.66        1.10      2.48    0.015
                                Stage 2                       3.11        2.04      4.76    \<0.001
                                Stage 3                       3.80        2.25      6.42    \<0.001
                                Stage 4                       5.87        3.15      10.97   \<0.001
                                Unknown                       1.90        1.16      3.10    0.011
  Adjuvant therapy                                                                          
                                None                          Reference                     
                                Adjuvant therapy              0.77        0.62      0.96    0.02

HR = hazard ratio; CI = confidence interval; CCI = Charlson/Deyo comorbidity index; NOS = not otherwise specified.

DISCUSSION
==========

Despite a near linear improvement in median eLN from gastrectomy over the past decade, most US patients with node-negative gastric cancer received operations that failed to meet NCCN guidelines of retrieving ≥15 LNs. This concerning statistic suggests that surgeons nationwide may not understand the correlation between the systemic potential of gastric cancer and clearance of regional LNs, thus failing to perform the meticulous LN dissection necessary to achieve an optimal LN yield. University facilities may adhere more strictly to NCCN guidelines, as a study on 7 US universities reported a mean of 16 eLN, and our current study found that academic centers were more frequently associated with adequate oncologic lymphadenectomy \[[@B4]\].

The effect of eLN on western patients was explored by Smith et al. \[[@B16]\] with a retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 1999. They reported an association between increased number of eLN and improved survival in patients with T1-3, N0-1 gastric cancer \[[@B16]\]. However, given the increased utilization of NAT, as well as improvement in lymphadenectomy techniques, this analysis also includes antiquated treatment protocols \[[@B17]\]. Jin et al. \[[@B4]\] evaluated factors associated with recurrence and survival in 317 patients with node-negative gastric cancer from 2000--2012, and reported that eLN ≥15 was associated with improvements in overall survival, but not disease recurrence. However, given the small sample size and inclusion of exclusively university facilities, the authors conceded that the analysis may have been insufficiently powered \[[@B4]\]. To our knowledge, this is the first study to evaluate national treatment patterns and outcomes of node-negative gastric cancer after the formation of the Meta-Analysis Group in Cancer (MAGIC) though it did include data from years prior to the publication of the trial by Cunningham et al. \[[@B17]\] in 2006 which established NAT as standard of care. It also includes the largest number of western patients to undergo NAT or surgery for node-negative gastric cancer.

In our study, both in patients who received NAT and in those who underwent initial surgery, a greater number of eLN was associated with improved survival. A study by Deng et al. \[[@B18]\] of 112 Chinese patients with node-negative gastric cancer reported that eLN \>20 was associated with improved survival. Another study on 600 Chinese patients with node negative gastric cancer recently reported that eLN was the strongest independent prognostic predictor and urged eLN to be considered a mandatory requirement for improving prognostic evaluations \[[@B10]\]. An Italian study, pre-dating the MAGIC trial, of 301 node-negative patients from 1992--2002 reported an association between eLN \>25 and improved survival \[[@B19]\]. These studies all advocate for meticulous LN dissection and optimizing the number of harvested nodes.

To our knowledge, this is the largest and most contemporary study on western patients with node-negative gastric cancer treated at a wide spectrum of CoC-accredited facilities. However, there are some important limitations which should be considered when interpreting the results. The NCDB is a database sourced from hospital registry data from diverse institutions across the United States, and data recording may vary slightly from facility to facility. Furthermore, though the NCDB was designed to collect oncologic data, it lacks chemotherapy regimen, disease recurrence, disease-specific death, and complications data. Given the retrospective nature of this study, there likely exists a selection bias, with patients with more severe presentations treated more aggressively. Additionally, node-negative disease was defined as patients with AJCC pathologic N0 disease. The database does not specify why patients received NAT, but it is possible that patients with clinically node positive disease converted to pathologic node negative disease following NAT and would thus be included in this study. While the NCCN recommends examination of at least 15 LNs, this study included patients with suboptimal lymphadenectomies to provide a more complete overview of US gastric cancer care. However, sub-optimal lymphadenectomy was controlled for in the multivariable Weibull survival analyses. Most patients in this study underwent proximal gastrectomy, which could include patients with gastroesophageal junction cancer, which current NCCN guidelines classify as esophageal tumors. However, this study used the NCDB gastric participant user file (PUF), not the esophagus PUF, to reduce possible misclassification. To further account for this, the multivariable Weibull analyses controlled for tumor location. Finally, it is important to consider the differences in pathologic specimen evaluation between Eastern countries and the United States \[[@B20]\]. While Eastern surgeons dissect out each LN station, western surgeons typically submit specimens en bloc \[[@B21]\].

In conclusion, most US patients with node-negative gastric cancer receive a suboptimal lymphadenectomy. Even in node-negative disease, increasing the number of retrieved lymph nodes appears to have therapeutic and prognostic value, irrespective of initial treatment. This suggests a survival benefit to meticulous lymphadenectomy in western patients with node-negative gastric cancer.
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